Chronic Obstructive Pulmonary Disease
📧 Sign up to get email alerts when something new happens for Chronic Obstructive Pulmonary Disease.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-01-30FDA Approved: THEOPHYLLINE — Original Application (Leading Pharma, LLC)
FDA approved Leading Pharma, LLC's original ANDA for theophylline, authorizing a generic version of theophylline. The approval supports its …
-
FDA approval · 2023-01-26FDA Approved: BREZTRI — Supplemental Application (AstraZeneca Pharmaceuticals LP)
FDA approved a supplemental application for BREZTRI (budesonide, glycopyrrolate, and formoterol fumarate) from AstraZeneca, indicating an ap…
-
CLINICAL_TRIALS trial_result · 2023-01-23Clinical Trial Update: A Study to Assess Drug Absorption of Fixed Dose Combinations of Budesonide, Glycopyrronium, and Formoterol [Phase 1]
Phase 1 trial update evaluating absorption of fixed-dose combinations of budesonide, glycopyrronium, and formoterol in COPD patients.
-
CLINICAL_TRIALS trial_result · 2023-01-04Clinical Trial Update: A Study to Test a Potential New Treatment for COPD Patients Suffering From the Common Cold or Influenza [Phase 2]
Phase 2 trial update for a potential COPD treatment; study completed.
-
CLINICAL_TRIALS trial_result · 2022-12-28Clinical Trial Update: Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease [Phase 4]
Phase 4 trial investigating inhaled long-acting bronchodilators with or without inhaled glucocorticosteroids to prevent hospitalizations and…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-12-21FDA Approved: ARFORMOTEROL TARTRATE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical Industries' supplemental application for arformoterol tartrate, a generic inhaled long-acting beta-agonist u…
-
CLINICAL_TRIALS trial_result · 2022-12-20Clinical Trial Update: A Study to Assess the Safety, Tolerability, and Efficacy of ION-827359 in Participants With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis (CB) [Phase 2]
Phase 2 trial assessing safety, tolerability, and efficacy of ION-827359 in mild to moderate COPD with chronic bronchitis; study terminated …
-
CLINICAL_TRIALS trial_result · 2022-12-14Clinical Trial Update: Cell Therapy Associated With Endobronchial Valve [Phase 2, Phase 3]
A clinical trial update for a cell therapy combined with an endobronchial valve in COPD is currently recruiting in Phase 2 and Phase 3.
-
FDA label_change · 2022-12-02FDA Approved: TRELEGY ELLIPTA — Supplemental Application (GlaxoSmithKline LLC)
The FDA approved a supplemental application for TRELEGY ELLIPTA filed by GlaxoSmithKline, resulting in updated labeling. This represents a l…
-
CLINICAL_TRIALS trial_result · 2022-11-28Clinical Trial Update: Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD [Phase 2]
Phase 2 clinical trial evaluating CSJ117 for symptom relief, pharmacodynamics, and safety in patients with chronic obstructive pulmonary dis…
-
FDA approval · 2022-11-25FDA Approved: FORMOTEROL FUMARATE INHALATION SOLUTION — Original Application (Ritedose Pharmaceuticals, LLC)
The FDA approved an abbreviated new drug application for Formoterol Fumarate Inhalation Solution from Ritedose Pharmaceuticals as a generic …
-
EMA withdrawal · 2022-11-24EMA Lapsed: Temybric Ellipta (fluticasone furoate;umeclidinium bromide;vilanterol trifenatate) — GlaxoSmithKline Trading Services Limited
The EMA lists Temybric Ellipta as lapsed in the European market.
-
CLINICAL_TRIALS trial_result · 2022-11-22Clinical Trial Update: Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) [Phase 2]
Phase 2 proof-of-concept study assessing SAR440340 (anti-IL-33 mAb) for efficacy, safety, and tolerability in moderate-to-severe COPD; study…
-
CLINICAL_TRIALS trial_result · 2022-11-15Clinical Trial Update: Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD [Phase 4]
Phase 4 trial evaluating nebulized long-acting bronchodilators vs short-acting bronchodilators in hospitalized COPD exacerbation patients; f…
-
FDA approval · 2022-11-15FDA Approved: ARFORMOTEROL TARTRATE — Original Application (Lifestar Pharma LLC)
FDA approved the Original Application for ARFORMOTEROL TARTRATE (arformoterol tartrate) by Lifestar Pharma LLC as a generic inhalation produ…
-
CLINICAL_TRIALS research · 2022-11-07Clinical Trial Update: Pulmonary Embolism as a Cause of COPD Exacerbations [NA]
Clinical trial completion investigating pulmonary embolism as a contributing factor to exacerbations in chronic obstructive pulmonary diseas…
-
CLINICAL_TRIALS trial_result · 2022-11-02Clinical Trial Update: Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders With COPD Traveling to High Altitude [Phase 3]
Phase 3 trial evaluating acetazolamide effects on right heart function at rest in COPD patients traveling to high altitude, with unknown cur…
-
CLINICAL_TRIALS withdrawal · 2022-10-27Clinical Trial Update: Cardiac Effects of Spiolto®/Respimat® in Patients With Congestive Heart Failure and COPD [Phase 4]
Phase 4 trial investigating cardiac effects of Spiolto/Respimat in patients with COPD was withdrawn.
-
FDA approval · 2022-10-20FDA Approved: UMECLIDINIUM AND VILANTEROL ELLIPTA — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application for Umeclidinium bromide and vilanterol triflate Ellipta, submitted by Prasco Laboratories.
-
FDA approval · 2022-10-12FDA Approved: THEOPHYLLINE — Original Application (Teva Pharmaceuticals, Inc.)
The FDA approved an original application for a generic Theophylline product from Teva Pharmaceuticals.
-
CLINICAL_TRIALS trial_result · 2022-09-21Clinical Trial Update: Peak Inspiratory Flow Rates in Patients With COPD [NA]
A completed clinical trial report on peak inspiratory flow rates in patients with chronic obstructive pulmonary disease (COPD).
-
FDA approval · 2022-09-07FDA Approved: ROFLUMILAST — Original Application (Novadoz Pharmaceuticals LLC)
The FDA approved Novadoz Pharmaceuticals LLC's original application for roflumilast, enabling a generic version of the COPD medication to en…
-
CLINICAL_TRIALS withdrawal · 2022-09-02Clinical Trial Update: Sequential Endoscopic Lung Volume Reduction [Phase 3]
Phase 3 trial of sequential endoscopic lung volume reduction in emphysema/COPD has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2022-08-30Clinical Trial Update: RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative [Phase 3]
Phase 3 trial update for REdefining THerapy In Early COPD (RETHINC) completed; results posted in 2022.
-
CLINICAL_TRIALS withdrawal · 2022-08-30Clinical Trial Update: Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) [Phase 4]
A Phase 4 trial evaluating appropriate inhaler use in COPD has been withdrawn.